Menu
Back to User profile » Dr Hiroaki Iijima
Papers published by Dr Hiroaki Iijima:
DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
De Nigris V, Prattichizzo F, Iijima H, Ceriello A
Diabetes, Metabolic Syndrome and Obesity 2021, 14:1519-1531
Published Date: 6 April 2021
Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
Takahara M, Shiraiwa T, Matsuoka TA, Yamamoto K, Maeno Y, Shiraiwa Y, Yoshida Y, Katakami N, Iijima H, Katsumata H, Arakawa K, Hashimoto T, Shimomura I
Diabetes, Metabolic Syndrome and Obesity 2020, 13:4457-4468
Published Date: 18 November 2020
Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
Kawarasaki S, Sawazaki H, Iijima H, Ng SP, Kwon J, Mohri S, Iwase M, Jheng HF, Takahashi H, Nomura W, Inoue K, Kawada T, Goto T
Diabetes, Metabolic Syndrome and Obesity 2020, 13:4353-4359
Published Date: 16 November 2020
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Diabetes, Metabolic Syndrome and Obesity 2018, 11:835-843
Published Date: 27 November 2018
Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 diabetes mellitus
Gouda M, Matsukawa M, Iijima H
Diabetes, Metabolic Syndrome and Obesity 2018, 11:647-658
Published Date: 17 October 2018